Reduced Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Receiving Long-Term Besifovir Therapyopen access
- Authors
- Yim, Hyung Joon; Kang, Seong Hee; Jung, Young Kul; Ahn, Sang Hoon; Kim, Won; Yang, Jin Mo; Jang, Jae Young; Kweon, Yong Oh; Cho, Yong Kyun; Kim, Yoon Jun; Hong, Gun Young; Kim, Dong Joon; Sohn, Joo Hyun; Lee, Jin Woo; Park, Sung Jae; Yim, Sun Young; Park, Jin Kyung; Um, Soon Ho
- Issue Date
- Mar-2024
- Publisher
- MDPI
- Keywords
- antivirals; cancer; carcinogenesis; complications; hepatitis B virus; liver tumor; nucleotide analogues; performance; prediction model; risk reduction
- Citation
- CANCERS, v.16, no.5
- Journal Title
- CANCERS
- Volume
- 16
- Number
- 5
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/26351
- DOI
- 10.3390/cancers16050887
- ISSN
- 2072-6694
2072-6694
- Abstract
- Simple Summary Further information is necessary regarding the influence of besifovir (BSV), a new nucleotide analogue, on the occurrence of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). When we compared the HCC incidence in non-cirrhotic CHB patients receiving BSV with the predicted number derived from the REACH-B (risk estimation for HCC in CHB) model, the standardized incidence ratio (SIR) was significantly reduced to 0.128 at 7 years. The incidence of HCC in patients with cirrhosis was compared using the GAG-HCC (guide with age, gender, HBV DNA, core promotor mutation, and cirrhosis) model, and the SIR was significantly decreased to 0.371 at 7.5 years. HCC prediction was available for BSV-treated patients using existing models. We concluded that BSV decreases the risk of HCC in patients with CHB, and HCC risk prediction models are applicable.Abstract No information is available regarding the influence of besifovir (BSV), a new nucleotide analogue, on the occurrence of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). This study evaluated the reduced risk of HCC in patients undergoing BSV treatment. A total of 188 patients with CHB were treated with BSV for up to 8 years. We prospectively assessed the incidence of HCC compared with the risk from prediction models. During the follow-up, 5 patients developed HCC: 1 of 139 patients with non-cirrhotic CHB, and 4 of 49 patients with liver cirrhosis. We compared the HCC incidence in non-cirrhotic and cirrhotic patients with the predicted number derived from the REACH-B (risk estimation for HCC in CHB) model and GAG-HCC (guide with age, gender, HBV DNA, core promotor mutation, and cirrhosis) model, respectively. The standardized incidence ratio (SIR) was 0.128 (p = 0.039) at 7 years in non-cirrhotic CHB patients, and the SIR was 0.371 (p = 0.047) at 7.5 years in cirrhotic patients, suggesting a significantly decreased HCC incidence in both groups. HCC prediction was available for BSV-treated patients using existing models. In conclusion, BSV decreased the risk of HCC in patients with CHB, and prediction models were applicable. Clinical trial registry website and trial number: ClinicalTrials.gov no: NCT01937806.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Internal Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/26351)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.